Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The Knee Explant Analysis (KnEA) Study

Microbiol Spectr. 2021 Dec 22;9(3):e0187921. doi: 10.1128/Spectrum.01879-21. Epub 2021 Nov 24.

Abstract

PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections (n = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log10 reduction (range, 1 to 7) in the bacterial CFU identified from the implants. IMPORTANCE Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. A mean 4-log10 reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee.

Keywords: PJI; PLG0206; biofilms.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimicrobial Peptides / administration & dosage*
  • Arthroplasty, Replacement, Knee / adverse effects*
  • Bacteria / drug effects*
  • Bacteria / growth & development
  • Humans
  • In Vitro Techniques
  • Knee / microbiology
  • Knee / surgery
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / microbiology
  • Prospective Studies
  • Prosthesis-Related Infections / drug therapy*
  • Prosthesis-Related Infections / microbiology

Substances

  • Antimicrobial Peptides